Kornimate/medical-research-clean huggingface dataset:
macugen for histoplasmosis

Conditions: Ocular Histoplasmosis; Choroidal Neovascularization

Summary: the purpose of this study is to evaluate the safety and effect on visual acuity of macugen (pegaptanib sodium) in patients with subfoveal choroidal neovascularization (cnv) secondary to the ocular histoplasmosis syndrome (ohs).

ocular histoplasmosis is a leading cause of severe and irreversible central vision loss in middle-aged adults living in the central and eastern us. ohs has been associated with the fungus histoplasma capsulatum, a dimorphic soil mold found in 18 to 20 states in the central and eastern us. annually, approximately 100,000 people are thought to be at risk of vision loss caused by ohs. this study will include ohs patients with cnv lesions no larger than 5400 microns in greatest linear diameter with classic or occult cnv extending under the geometric center of the faz and best-corrected visual acuity letter score between 20/40-20/200. twenty four patients will be enrolled and the study will have 2 treatment arms with 12 patients each. the first arm will consist of 12 patients who will receive 0.3 mg of macugen intravitreally every 6 weeks for one year. the second arm will consist of 12 patients who will receive photodynamic therapy (pdt) with visudyne every 3 months for one year.

Eligibility criteria:
inclusion criteria: * diagnosis of ocular histoplasmosis, * evidence of classic or occult choroidal neovascularization extending under the geometric center of the fovea, * greatest linear diameter of no greater than 5400 microns, * best-corrected visual acuity scores between 20/40-20/200, * ability to give informed consent, * limited child bearing potential and a negative pregnancy test exclusion criteria: * features of any condition other than ohs such as amd, or pathologic or myopic angioid streaks associated with cnv in the study eye, * area of cnv that is less than 50% of the total lesion not including area of prior laser treatment, previous rip of retinal pigment epithelium, * vitelliform-like lesion, * telangiectasia, * central serous retinopathy, * serous pigment epithelial detachment without cnv, * any significant ocular disease other than cnv that could compromise vision in the study eye, such as amblyopia, glaucoma, optic neuropathy, or diabetic retinopathy, * inability to obtain photographs to document cnv, * presence of atrophy/scar in the center of fovea, * presence of vitreo-retinal traction over the center of the fovea, * history of treatment for cnv in the study eye other than non-foveal laser photocoagulation,within 12 weeks prior to enrollment * participation in another clinical trial or use of another investigational new drug within 12 weeks of the full extent of the study treatment, * intraocular surgery within the last two months, * capsulectomy within the last month in the study eye

Keywords: ocular histoplasmosis macugen photodynamic therapy with visudyne best-corrected visual acuity scores between 20/40-20/200 classic or occult choroidal neovascularization
mindfulness based therapy for insomnia in black women

Conditions: Insomnia

Summary: the purpose of the study is to conduct an 8-week rct to improve insomnia among black women with insomnia and evaluate its feasibility, acceptability, and efficacy of mindfulness based therapy for insomnia (mbti)

study design is a randomized clinical trial (rct) with attention control. participants will be randomly assigned to participate in either mindfulness based therapy for insomnia (mbti) or time and attention control. participants in the experimental group will receive the mbti that includes mindfulness meditation and behavioral strategies for sleep. participants in the control group will receive healthy lifestyle education that includes healthy eating, physical activity and sleep hygiene practice to mitigate insomnia.

Eligibility criteria:
inclusion criteria: * self-identified black women * 25-45 years old * english speaking * meeting dsm-5/icsd3 diagnostic criteria for insomnia disorders defined as difficulty initiating or maintaining sleep with at least one associated daytime impairment symptom (insomnia severity index \> 7) exclusion criteria: * psychosis or unstable/ significant depression, anxiety, or substance abuse under active care (more than 1 monthly mental healthcare visit or requiring more than 1 psychotropic medicine daily) * significant current practice of any form of meditation (\>15min per day) * obstructive sleep apnea (osa), restless legs syndrome (rls), or circadian rhythm related condition (shift worker, pregnancy, use of medication that influence circadian rhythm, e.g., parkinson's disease) * other medical conditions that confound salivary biomarkers outcomes (e.g., radiation of salivary glands, cushing or addison's disease) * active or terminal cancer

Keywords: mindfulness-based therapy for insomnia (mbti)
quantitative evaluation of bitter taste in obesity

Conditions: Obesity

Summary: although taste influences food choices and favours diseases like obesity, there is no consensus about the existence of correlations between bitterness and anthropometric variables. also, an electronic-based method for data collection could provide a more appropriate way for the evaluation of taste perception and save time. the objective is to search for correlations between bitterness and anthropometric variables.

a cross-sectional study evaluating correlations between the bitterness rates given on a generalized labeled magnitude scale, anthropometrics and other variables. bitterness perceptions at the tip of the tongue (totp) and at the whole mouth (wmp) were recorded using a locally developed novel cloud-based software (cloud-glms). the ancova test was adjusted using totp and wmp as dependent variables and age, height, weight, bmi, gender, waist circumference, alcohol intake, comorbidities, and use of medications as independent variables.

Eligibility criteria:
inclusion criteria: * weight limit of 150 kg and who are able to read the text with the guidelines on how to be punctuated the sensation of bitter in the generalized labeled scale. exclusion criteria: * being a relative of the first degree of a patient already included in the research, tobacco in the forms of cigarettes, pipes and cigars in the last 30 days, presence of coryza, nasal congestion or frequent sneezing, dental treatment on the same day of the research. being a dementia sufferer, having an altered, drowsy level of consciousness. show upper limb tremor visible.
evaluation of the zilver vascular stent in the iliac arteries (zips)

Conditions: Peripheral Arterial Disease (PAD)

Summary: the purpose of this study is to assess the ability of a vascular stent to maintain an open iliac (leg) artery. the zilver vascular stent is made of nitinol, a flexible metal with a long history of use in medical devices. the stent self-expands once inside the artery where it is intended to hold the vessel wall open. within a few weeks, a layer of cells will grow over the stent helping to hold it in place.


Eligibility criteria:
inclusion criteria: * patient has documented stenotic or occluded atherosclerotic lesions of the external iliac or common iliac artery. * patient has a de novo or restenotic lesion(s) with no prior stent in the target lesion. * patient has given informed consent. exclusion criteria: * patient is less than 50 years of age * patient is participating in another investigational drug or device study. * patient has multiple lesions (ipsilateral or in the aorta) that would require a staged procedure. * patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions. * patient has a known hypersensitivity or contraindication to aspirin, clopidogrel, nitinol, or contrast dye that cannot be adequately premedicated. * patient is pregnant or breast-feeding.
understanding the mechanism(s) of action on the modified atkins diet for epilepsy: human brain tissues

Conditions: Epilepsy

Summary: the purpose of this study is to better define the potential molecular and anti-inflammatory changes induced by the modified atkins diet in the brains of patients with treatment resistant epilepsy. the investigators plan to enroll 30 subjects overall in this study to compare serologic and brain tissue specimens. at nyu, investigators plan to enroll 20 subjects; an estimated ten (10) subjects will consume a modified atkins diet for 3-4 weeks prior to surgery and an estimated ten (10) subjects will consume a non-modified, higher carbohydrate diet. investigators at saint barnabas medical center plan to enroll 10 subjects in this study to compare serologic and brain tissue specimens. approximately five (5) subjects will consume a modified atkins diet for 3-4 weeks prior to surgery and five (5) subjects will consume a non-modified, higher carbohydrate diet. blood and brain tissue specimens will be obtained at the time of surgery and will be compared. the goal of this study is to identify whether or not there are changes in neuroinflammation or neuroexcitability in the human brain induced by the modified atkins diet.


Eligibility criteria:
inclusion criteria: patients scheduled for epilepsy surgery at new york langone medical center or st barnabas medical center will be eligible for enrollment. * patient is at least 18 years of age * patient is willing to participate by complying with the modified atkins diet 3 - 4 weeks prior to surgery and maintain a thorough food diary (intervention study group) or to continue their usual diet and maintain a thorough food diary (nonintervention study group) * patient/ his/her parent, caregiver, or health care proxy is willing and able to provide consent or assent exclusion criteria: * patients under the age of 18 will be excluded * patients in whom a two-stage surgery is planned without any resection of brain tissue during the initial craniotomy * patients unwilling to comply with modified atkins diet 3 -4 weeks prior to surgery or unwilling to maintain a thorough food diary will be excluded. * patients who are currently on an atkins or low glycemic index diet will not be eligible for inclusion in the nonintervention group.
f18-flt pet/ct as a tool for assessment of myeloablative treatment in patients with acute myeloid leucemia(aml)

Conditions: Acute Myeloid Leucemia

Summary: pet/ct is reliable tool in evaluation of treatment response in number cancers. f18-flt is a precursor of dna with high uptake in the bone marrow as a part of normal biodistribution. highly increased uptake of this radiopharmaceutical was shown in a number of hematologic disease either in bone marrow or extramedullary. f18-flt pet/ct can provide a tool for whole body assessment of activity in bone marrow as well as early estimation of treatment efficacy or lack of it. in addition, this noninvasive study can replace bone marrow biopsy and predict response vs. non response to therapy.


Eligibility criteria:
inclusion criteria: * new diagnosis of aml exclusion criteria: * pregnancy

Keywords: flt pet bone marrow aml
immediate effects of stepping training using external feedback in spinal cord injury patients

Conditions: Spinal Cord Injuries

Summary: * does stepping training with or without external feedback change functional ability of ambulatory patients with isci immediately after training? * are there significant differences between the immediate effects of stepping training with or without external feedback in ambulatory patients with isci?

to compare immediate effects of stepping training with or without the utility of external feedback on functional ability relating to walking in ambulatory patients with isci (between-group comparison). secondary objective to compare immediate effects in a group of stepping training with or without the utility of external feedback on functional ability relating to walking in ambulatory patients with isci (within-group comparison).

Eligibility criteria:
inclusion criteria: * independent ambulatory patients with isci at a chronic stage (post-injury time \> 12 months) * traumatic cause or non-progressive disease * independent walking with or without assistive devices at least 17 meters (functional independence measure locomotor (fim-l) scores 5-7) * age at least 18 years * body mass index (bmi) between 18.5 - 29.9 kg/m2. exclusion criteria: * any conditions or disorders that might affect ability to participate in the study and/or ambulatory ability of the subjects such as * brain function disorders * visual deficits that cannot be corrected using glasses or contact lens * musculoskeletal pain (with an intensity of pain more than 5 out of 10 on a numerical rating pain scale) * deformity of the musculoskeletal system * unable to follow a command of the tests * unstable medical conditions * color blindness

Keywords: rehabilitation neurological condition walking ability feedback external information
the effect of tamsulosin on postoperative urinary retention

Conditions: Urinary Retention

Summary: this is a double-blinded randomized controlled trial of perioperative use of tamsulosin to prevent postoperative urinary retention in female pelvic reconstructive surgery undergoing same-day discharge with an enhanced recovery after surgery protocol.

the primary objective is to determine the effect of tamsulosin on same-day active voiding trial in women undergoing female pelvic reconstructive surgery with vaginal native tissue repair with same-day discharge planned. duration of catheterization, postoperative urinary tract infection rates, patient level of satisfaction, emergency department (ed) visits and adverse events postoperatively will also be compared between women receiving tamsulosin versus placebo. patients will be offered participation in the study at their postoperative visit if they meet study criteria. once consent is obtained, patients will be randomized to receive tamsulosin 0.4 mg orally once daily or matching placebo capsules for a total of 10 days starting 5 days pre-operatively.

Eligibility criteria:
inclusion criteria: * stage ii or greater pelvic organ prolapse in \> 1 vaginal compartment * plan for multicompartment native tissue vaginal repair (which would include any combination of uterosacral ligament suspension, sacrospinous ligament suspension, cystocele and/or rectocele repair, with or without hysterectomy and with or without concomitant mid-urethral sling) or vaginal closure with female pelvic medicine and reconstructive surgery (fpmrs) - trained surgeons at wake forest baptist health * participation in enhanced-recovery-after-surgery protocol with plan for same-day hospital discharge * willing to remain compliant with investigation product (ip) exclusion criteria: * intraoperative complication necessitating prolonged bladder drainage or placement of a vaginal pack x 24 hours (patients would exit study after randomization and will be excluded from the per-protocol analysis) * patients whose surgical plan would necessitate a voiding trial on postop day \>0 * less than 21 years of age * unable to understand english * patients who are scheduled to undergo combined colorectal procedures such as rectopexy, sphincteroplasty * patient with known allergy to tamsulosin or sulfa drugs * patients with upcoming cataract surgery * patient with orthostatic hypotension * history of postvoid residual (pvr\>150) prior to surgery with prolapse reduction * patients with hypertension on alpha-blockers * single compartment prolapse repair (anterior or posterior repair only) * use of mesh for prolapse repair * high tone pelvic floor dysfunction

Keywords: postoperative care urinary tract infection female pelvic reconstructive surgery enhanced recovery after surgery tamsulosin flomax
long-term effects of iodine i tositumomab and autologous bone marrow or stem cell transplantation in patients with relapsed or refractory non-hodgkin's lymphoma

Conditions: Lymphoma; Quality of Life

Summary: rationale: studying the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care. purpose: this phase ii trial is studying the long-term effects of iodine i 131 tositumomab and autologous bone marrow or stem cell transplantation in patients with relapsed or refractory non-hodgkin's lymphoma.

objectives: * determine the progression-free survival and overall survival of patients with relapsed or refractory b-cell non-hodgkin's lymphoma previously treated with iodine i\^131 tositumomab followed by autologous bone marrow or stem cell transplantation on fhcrc protocols 296, 521, 792, or 915. * determine the long-term toxic effects of this regimen in these patients. * determine the quality of life of patients treated with this regimen. outline: this is a long-term, follow-up study. patients undergo testing for human anti-mouse antibody at 1, 3 and 12 months. patients undergo physical examinations, blood tests, and immune system assessments every 3 months for 1 year and then annually thereafter. thyroid, pulmonary, and cardiac function are assessed at 1 year and then annually as needed. patients also undergo ct scans and bone marrow biopsy (if clinically indicated) annually for up to 10 years. quality of life is assessed annually. projected accrual: a total of 47 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of b-cell non-hodgkin's lymphoma * relapsed or refractory disease * previously treated with myeloablative doses of iodine i\^131 tositumomab and autologous bone marrow or stem cell transplantation on 1 of the following phase i or ii protocols: * fhcrc-296 * fhcrc-521 * fhcrc-792 * fhcrc-915 patient characteristics: age * 18 and over performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified prior concurrent therapy: biologic therapy * see disease characteristics chemotherapy * not specified endocrine therapy * not specified radiotherapy * see disease characteristics surgery * not specified

Keywords: quality of life recurrent adult burkitt lymphoma recurrent adult diffuse large cell lymphoma recurrent adult diffuse mixed cell lymphoma recurrent adult diffuse small cleaved cell lymphoma recurrent adult immunoblastic large cell lymphoma recurrent adult lymphoblastic lymphoma recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma recurrent grade 3 follicular lymphoma recurrent small lymphocytic lymphoma recurrent mantle cell lymphoma recurrent marginal zone lymphoma waldenstrom macroglobulinemia recurrent adult grade iii lymphomatoid granulomatosis splenic marginal zone lymphoma extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue nodal marginal zone b-cell lymphoma
cardiac manifestation and inherited metabolic diseases

Conditions: Metabolism, Inborn Errors

Summary: the aim of this study is to report and describe cardiac manifestations associated with imd in a cohort of patients followed in a reference center for rare diseases (lausanne university hospital, chuv) from 2017-2020.

inherited metabolic diseases (imd) are genetic disorders resulting from an enzyme defect and/or transport proteins in metabolic pathways affecting proteins, fat, carbohydrate metabolism or impaired organelle function. as imds can affect the primary sources of energy (glycogen, fatty acids), they can lead to cardiac dysfunction. although most of imds are multisystemic diseases, in some cases, the cardiac dysfunction they cause is the main clinical feature and source of major complications which will determine the prognosis, like heart failure, ventricular arrythmias or even sudden death. information regarding cardiac manifestations in adult imds is currently scarce and little is known about their clinical and radiological characteristics. a database was created in 2017 including all patients with imd followed at the adult metabolic clinic in the chuv. this database was part of a protocol submitted and approved by the ethics committee (# 2017-02328). the results of this first analysis were published in the journal of orphan rare diseases. investigators will use this database to identify all the patients who had cardiac examination. only patients from the lausanne university hospital followed jointly with the division of cardiology will be included in the analysis. electronic and paper patient charts from the division of genetic medicine and division of cardiology (lausanne university hospital) will be reviewed for type of imd and cardiac investigations (cardiac ultrasound, multiple resonance imaging, electrocardiogram). all variables will be entered in an excel database.

Eligibility criteria:
inclusion criteria: * all imd adult patients followed at the adult metabolic clinic at the lausanne university hospital from 2017 to 2020 with cardiac investigations exclusion criteria: * age \< 16 years. any document attesting a refusal to participate will exclude the data entry of the concerned patient

Keywords: cardiac involvement inborn errors of metabolism
diamine oxidase and adverse pregnancy outcomes

Conditions: Pregnancy Complications

Summary: in normal pregnancies, blood histamine concentration remains within normal values; however, the serum histaminolytic activity is increased. histamine is mainly produced by mast cells, platelets, basophils, neurons and enterochromatin cells, where it is stored and released when required. reduced dao activities have been found in high-risk pregnancies. lower dao activity has been associated to miscarriage, fetal demise, preeclampsia, low birthweight and preterm birth. the placenta is very rich in dao activity and is the principal source of increased histaminolytic activity in normal pregnancies. first-trimester screening for preeclampsia (pe) is a routine screening which is performed in the first trimester. women with a positive result are at a greater risk of pe but also other pregnancy complications such as stillbirth, preterm birth and low birthweight. these cases are prescribed aspirin until term. this intervention has demonstrated to significantly reduce the risk of pe and other complications. unfortunately, aspirin does not avoid all cases with adverse outcomes, indicating that additional mechanisms may be involved in the development of such pregnancy complications, such as dao decreased activity.


Eligibility criteria:
inclusion criteria: * single pregnancy * maternal age ≥18 * high risk (≥1/50) in the first-trimester screening for preeclampsia * gestational age between 11+0 and 16+6 weeks of gestation exclusion criteria: * fetal malformation * fetal death * maternal digestive inflammatory disease or intolerance * refusal to give informed consent

Keywords: preeclampsia pprom preterm birth fetal death low birthweight
impact of sub-anesthetic dose of ketamine on post spinal hypotension in caesarean delivery

Conditions: Anesthesia

Summary: the purpose of this study is to evaluate the effect of sub anesthetic dose of ketamine on vasopressor (ephedrine) requirement to prevent maternal hypotension after spinal anesthesia in caesarean section.


Eligibility criteria:
inclusion criteria: * physical status american society of anesthesiologist(asa) i or ii. full term pregnancy exclusion criteria: * ,pre-eclampsia. * chronic hypertension. * cardiovascular troubles. * any contraindications to spinal anesthesia as back infection , coaguolopathy , patient refusal